MedTrace Logo

A Study of ZN-c5 in Participants With Breast Cancer

NCT04176757 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2022-08-01

No results posted yet for this study

Summary

This is a Phase 1 open-label, multicenter study to evaluate biomarkers for ZN-c5 in subjects with breast cancer

Conditions

Interventions

DRUG

ZN-c5

ZN-c5 study drug to be administered orally daily

Sponsors & Collaborators

  • Zeno Alpha Inc.

    lead INDUSTRY

Principal Investigators

  • Mieke Ptaszynski, MD · Zeno Alpha Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-03
Primary Completion
2021-04-27
Completion
2021-05-25
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bosnia and Herzegovina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04176757 on ClinicalTrials.gov